Related Experiment Videos
Cardiac complications of end-stage renal disease
1Department of Medicine, Georgetown University Medical Center, Washington, DC, USA.
Insights
Cardiovascular disease is a major concern for dialysis patients due to shared risk factors with end-stage renal disease. Management focuses on risk factor modification, medical therapies, and revascularization strategies for better outcomes.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Cardiovascular disease (CVD) is the primary cause of mortality in patients undergoing dialysis, stemming from shared risk factors with end-stage renal disease (ESRD).
- Established CVD risk factors like diabetes mellitus, hypertension, dyslipidemia, and smoking are prevalent in this population.
- Additional contributing factors include hyperparathyroidism, hypoalbuminemia, hyperhomocysteinemia, elevated apolipoprotein (a), and dialysis membrane type.
Purpose of the Study:
- To outline the key cardiovascular risks and management strategies for patients on dialysis.
- To highlight the specific challenges and therapeutic approaches for coronary artery disease, congestive heart failure, and pericarditis in dialysis patients.
Main Methods:
- Review of established risk factors for coronary artery disease in the dialysis population.
- Discussion of medical management including risk factor modification, aspirin, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, and lipid-lowering agents.
- Evaluation of revascularization techniques, favoring coronary artery bypass grafting (CABG) over percutaneous transluminal coronary angioplasty (PTCA) in specific patient subgroups.
Main Results:
- Coronary artery bypass grafting is often preferred over percutaneous transluminal coronary angioplasty for revascularization, particularly in patients with multivessel disease, impaired left ventricular function, severe symptoms, or ischemia.
- Angiotensin-converting enzyme (ACE) inhibitors and beta blockers are considered first-line therapies for congestive heart failure in dialysis patients.
- Erythropoietin is crucial for managing anemia, though optimal hemoglobin levels remain under investigation. Peritoneal dialysis may benefit severe heart failure cases.
Conclusions:
- Comprehensive management of cardiovascular disease in dialysis patients requires addressing traditional and ESRD-specific risk factors.
- Aggressive medical therapy and judicious use of revascularization procedures are essential.
- Further research is needed to optimize therapies like erythropoietin for anemia in this vulnerable population.
Abstract:
Cardiovascular disease is the leading cause of death in patients receiving dialysis. This is attributed in part to the shared risk factors of cardiovascular disease and end-stage renal disease. The risk factors for coronary artery disease include the classic cardiac risk factors of diabetes mellitus, hypertension, dyslipidemia, and smoking. Also in this population, hyperparathyroidism, hypoalbuminemia, hyperhomocysteinemia, elevated levels of apolipoprotein (a), and the type of dialysis membrane may play a role. Management begins with risk factor modification and medical therapy including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and lipid-lowering agents. Revascularization is often important, and coronary artery bypass grafting appears to be preferable to percutaneous transluminal coronary angioplasty. This is especially true for those with multivessel disease, impaired left ventricular function, severe symptoms, or ischemia. Congestive heart failure is another common problem in dialysis patients. The management includes correction of underlying abnormalities, optimal dialysis, and medical therapy. Data obtained from the general population indicate obvious benefits from ACE inhibitors and beta blockers, and these agents would be considered the therapies of choice. Erythropoetin is also an essential component of therapy, but the ideal hemoglobin concentration has yet to be determined. Peritoneal dialysis may be helpful in severe cases of heart failure. Pericarditis is seen in less than 10% of dialysis patients and is best diagnosed by clinical examination and echocardiography. Intensive dialysis is often the best initial therapy. Pericardiocentesis is reserved for the setting of pericardial tamponade, but a pericardial window is more definitive.